tetano
Editor, Senior Moderator
Expert Rev Vaccines
. 2020 Sep 17.
doi: 10.1080/14760584.2020.1825951. Online ahead of print.
Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks and public health considerations
Janet Sultana[SUP] 1 [/SUP], Giampiero Mazzaglia[SUP] 2 [/SUP], Nicoletta Luxi[SUP] 1 [/SUP], Antonino Cancellieri[SUP] 3 [/SUP], Annalisa Capuano[SUP] 4 5 [/SUP], Carmen Ferrajolo[SUP] 4 5 [/SUP], Chiara de Waure[SUP] 6 [/SUP], Guido Ferlazzo[SUP] 3 [/SUP], Gianluca Trifir?[SUP] 1 [/SUP]
Affiliations
Abstract
Introduction: Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), has quickly spread around the world.
Areas covered: This review will discuss the available immunologic and clinical evidence to support the benefit of the influenza, pneumococcal and tuberculosis vaccines in the prevention of COVID-19 and in the prognosis improvement of COVID-19 patients as well as to provide an updated overview on the COVID-19-specific vaccines that are in the development pipeline. In addition, implications for vaccination strategies from a public health perspective will be discussed.
Expert opinion: Some commonly used vaccines are being considered for their potentially beneficial role in preventing or improving the prognosis of COVID-19: influenza, pneumococcal and tuberculosis vaccines. These vaccines may have either direct effect on COVID-19 via different types of immune responses or indirect effects by reducing the burden of viral and bacterial respiratory diseases on individual patients and national healthcare system and by facilitating differential diagnoses with other viral/bacterial respiratory disease. The latter may ultimately allow a more rapid SARS-CoV-2 infected patient isolation and contact tracing. On the other hand, a large number of candidate vaccines against SARS-CoV-2 are currently in the pipeline and undergoing phase I, II and III clinical studies. As SARS-CoV-2 vaccines are expected to be marketed through accelerated regulatory pathways, vaccinovigilance as well as planning of a successful vaccination campaign will play a major role.
Keywords: BCG vaccine; COVID-19; influenza vaccine; pneumococcal vaccine; vaccination campaign; vaccines; vaccinovigilance.
. 2020 Sep 17.
doi: 10.1080/14760584.2020.1825951. Online ahead of print.
Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks and public health considerations
Janet Sultana[SUP] 1 [/SUP], Giampiero Mazzaglia[SUP] 2 [/SUP], Nicoletta Luxi[SUP] 1 [/SUP], Antonino Cancellieri[SUP] 3 [/SUP], Annalisa Capuano[SUP] 4 5 [/SUP], Carmen Ferrajolo[SUP] 4 5 [/SUP], Chiara de Waure[SUP] 6 [/SUP], Guido Ferlazzo[SUP] 3 [/SUP], Gianluca Trifir?[SUP] 1 [/SUP]
Affiliations
- PMID: 32940090
- DOI: 10.1080/14760584.2020.1825951
Abstract
Introduction: Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), has quickly spread around the world.
Areas covered: This review will discuss the available immunologic and clinical evidence to support the benefit of the influenza, pneumococcal and tuberculosis vaccines in the prevention of COVID-19 and in the prognosis improvement of COVID-19 patients as well as to provide an updated overview on the COVID-19-specific vaccines that are in the development pipeline. In addition, implications for vaccination strategies from a public health perspective will be discussed.
Expert opinion: Some commonly used vaccines are being considered for their potentially beneficial role in preventing or improving the prognosis of COVID-19: influenza, pneumococcal and tuberculosis vaccines. These vaccines may have either direct effect on COVID-19 via different types of immune responses or indirect effects by reducing the burden of viral and bacterial respiratory diseases on individual patients and national healthcare system and by facilitating differential diagnoses with other viral/bacterial respiratory disease. The latter may ultimately allow a more rapid SARS-CoV-2 infected patient isolation and contact tracing. On the other hand, a large number of candidate vaccines against SARS-CoV-2 are currently in the pipeline and undergoing phase I, II and III clinical studies. As SARS-CoV-2 vaccines are expected to be marketed through accelerated regulatory pathways, vaccinovigilance as well as planning of a successful vaccination campaign will play a major role.
Keywords: BCG vaccine; COVID-19; influenza vaccine; pneumococcal vaccine; vaccination campaign; vaccines; vaccinovigilance.